Posaconazole

Posaconazole
Clinical data
Trade names	Noxafil, Posanol, others
AHFS/Drugs.com	Monograph
MedlinePlus	a607036
License data	EU EMA: by INN; US DailyMed: Posaconazole; US FDA: Posaconazole;
Pregnancy; category	AU: B3; ;
Routes of; administration	By mouth, intravenous
ATC code	J02AC04 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	Low (8 to 47% Oral)
Protein binding	98 to 99%
Metabolism	Liver (glucuronidation)
Elimination half-life	16 to 31 hours
Excretion	Fecal (71–77%) and Kidney (13–14%)
Identifiers
	IUPAC name 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furanyl]methoxy]phenyl]-1-piperazinyl]phenyl]-2-[(1S,2S)-1-ethyl-2- hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one;
CAS Number	171228-49-2 ;
PubChem CID	147912;
DrugBank	DB01263 ;
ChemSpider	130409 ;
UNII	6TK1G07BHZ;
KEGG	D02555 ;
ChEBI	CHEBI:64355 ;
ChEMBL	ChEMBL1397 ;
CompTox Dashboard (EPA)	DTXSID6049066 ;
ECHA InfoCard	100.208.201
Chemical and physical data
Formula	C37H42F2N8O4
Molar mass	700.792 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C1N(/N=C\N1c2ccc(cc2)N7CCN(c6ccc(OCC3C[C@@](OC3)(c4ccc(F)cc4F)Cn5ncnc5)cc6)CC7)[C@@H](CC)[C@@H](O)C;
	InChI InChI=1S/C37H42F2N8O4/c1-3-35(26(2)48)47-36(49)46(25-42-47)31-7-5-29(6-8-31)43-14-16-44(17-15-43)30-9-11-32(12-10-30)50-20-27-19-37(51-21-27,22-45-24-40-23-41-45)33-13-4-28(38)18-34(33)39/h4-13,18,23-27,35,48H,3,14-17,19-22H2,1-2H3/t26-,27?,35-,37-/m0/s1 ; Key:RAGOYPUPXAKGKH-AGDNISCASA-N ;
	(what is this?) (verify)

Posaconazole, sold under the brand name Noxafil among others, is a triazole antifungal medication.^[7]^[8]

It was approved for medical use in the United States in September 2006,^[5]^[9] and is available as a generic medication.^[10]^[11]

^ "Posaconazole (Noxafil) Use During Pregnancy". Drugs.com. 23 April 2019. Archived from the original on 30 January 2020. Retrieved 30 January 2020.
^ "Posaconazole suspension ARX/Posaconazole TIH/APX-Posaconazole (Arrow Pharma Pty Ltd)". Therapeutic Goods Administration (TGA). 16 February 2023. Archived from the original on 18 March 2023. Retrieved 29 April 2023.
^ "Posanol Product information". Health Canada. 25 April 2012. Archived from the original on 16 May 2021. Retrieved 3 July 2022.
^ "Noxafil 100 mg Gastro-resistant Tablets - Summary of Product Characteristics (SmPC)". (emc). 10 January 2022. Archived from the original on 24 February 2022. Retrieved 3 July 2022.
^ ^a ^b Cite error: The named reference Noxafil FDA label was invoked but never defined (see the help page).
^ "Noxafil EPAR". European Medicines Agency. 17 September 2018. Archived from the original on 19 October 2021. Retrieved 3 July 2022.
^ Schiller DS, Fung HB (September 2007). "Posaconazole: an extended-spectrum triazole antifungal agent". Clinical Therapeutics. 29 (9): 1862–86. doi:10.1016/j.clinthera.2007.09.015. PMID 18035188.
^ Rachwalski EJ, Wieczorkiewicz JT, Scheetz MH (October 2008). "Posaconazole: an oral triazole with an extended spectrum of activity". The Annals of Pharmacotherapy. 42 (10): 1429–38. doi:10.1345/aph.1L005. PMID 18713852. S2CID 21777822. Retrieved 11 December 2008.^{[dead link]}
^ "Drug Approval Package: Noxafil (Posaconazole) NDA #022003". U.S. Food and Drug Administration (FDA). 9 November 2006. Archived from the original on 3 April 2021. Retrieved 15 August 2020.
^ "Posaconazole: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 20 October 2020. Retrieved 15 August 2020.
^ "First Generic Drug Approvals". U.S. Food and Drug Administration. 17 October 2022. Archived from the original on 26 January 2021. Retrieved 28 November 2022.

[Drugs.com_pregnancy-1] "Posaconazole (Noxafil) Use During Pregnancy". Drugs.com. 23 April 2019. Archived from the original on 30 January 2020. Retrieved 30 January 2020.

[2] "Posaconazole suspension ARX/Posaconazole TIH/APX-Posaconazole (Arrow Pharma Pty Ltd)". Therapeutic Goods Administration (TGA). 16 February 2023. Archived from the original on 18 March 2023. Retrieved 29 April 2023.

[3] "Posanol Product information". Health Canada. 25 April 2012. Archived from the original on 16 May 2021. Retrieved 3 July 2022.

[4] "Noxafil 100 mg Gastro-resistant Tablets - Summary of Product Characteristics (SmPC)". (emc). 10 January 2022. Archived from the original on 24 February 2022. Retrieved 3 July 2022.

[Noxafil_FDA_label-5] Cite error: The named reference Noxafil FDA label was invoked but never defined (see the help page).

[Noxafil_EPAR-6] "Noxafil EPAR". European Medicines Agency. 17 September 2018. Archived from the original on 19 October 2021. Retrieved 3 July 2022.

[pmid18035188-7] Schiller DS, Fung HB (September 2007). "Posaconazole: an extended-spectrum triazole antifungal agent". Clinical Therapeutics. 29 (9): 1862–86. doi:10.1016/j.clinthera.2007.09.015. PMID 18035188.

[pmid18713852-8] Rachwalski EJ, Wieczorkiewicz JT, Scheetz MH (October 2008). "Posaconazole: an oral triazole with an extended spectrum of activity". The Annals of Pharmacotherapy. 42 (10): 1429–38. doi:10.1345/aph.1L005. PMID 18713852. S2CID 21777822. Retrieved 11 December 2008.^{[dead link]}

[9] "Drug Approval Package: Noxafil (Posaconazole) NDA #022003". U.S. Food and Drug Administration (FDA). 9 November 2006. Archived from the original on 3 April 2021. Retrieved 15 August 2020.

[10] "Posaconazole: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 20 October 2020. Retrieved 15 August 2020.

[11] "First Generic Drug Approvals". U.S. Food and Drug Administration. 17 October 2022. Archived from the original on 26 January 2021. Retrieved 28 November 2022.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]